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ISBackground: Both T-cell activation during early HIV-1 infection and soluble markers of
immune activation during chronic infection are predictive of HIV disease progression.
Although the acute phase of HIV infection is associated with increased pro-inflamma-
tory cytokine production, the relationship between cytokine concentrations and HIV
pathogenesis is unknown.
Objectives: To identify cytokine biomarkers measurable in plasma during acute HIV-1
infection that predict HIV disease progression.
Design: Study including 40 South African women who became infected with HIV-1
and were followed longitudinally from the time of infection.
Methods: The concentrations of 30 cytokines in plasma from women with acute HIV-1
infection were measured and associations between cytokine levels and both viral load
set point 12 months postinfection and time taken for CD4 cell counts to fall below
350 cells/ml were determined using multivariate and Cox proportional hazards
regression.
Results: We found that the concentrations of five plasma cytokines, IL-12p40, IL-
12p70, IFN-g, IL-7 and IL-15 in women with acute infection predicted 66% of the
variation in viral load set point 12 months postinfection. IL-12p40, IL-12p70 and IFN-g
were significantly associated with lower viral load, whereas IL-7 and IL-15 were
associated with higher viral load. Plasma concentrations of IL-12p40 and granulo-
cyte–macrophage colony-stimulating factor during acute infection were associated
with maintenance of CD4 cell counts above 350 cells/ml, whereas IL-1a, eotaxin and IL-
7 were associated with more rapid CD4 loss.
Conclusion: A small panel of plasma cytokines during acute HIV-1 infection was
predictive of long-term HIV disease prognosis in this group of South African women.
 2010 Wolters Kluwer Health | Lippincott Williams & WilkinsAIDS 2010, 24:000–000Keywords: acute infection, cytokines, disease progression, HIV-1, viral loadippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
cal Virology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, bNational
Services, Cape Town, cCentre for the AIDS Programme of Research in South Africa, University of KwaZulu
epartment of Statistical Sciences, University of Cape Town, Cape Town, South Africa, eColumbia University,
ork, USA, and fDivision of Molecular Biology and Human Genetics, Stellenbosch University, Stellenbosch,
o Dr Jo-Ann S. Passmore, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town
nzio Road, Observatory, 7925 Cape Town, South Africa.
089; fax: +27 21 406 6681; e-mail: Jo-ann.Passmore@uct.ac.za
mber 2009; revised: 16 November 2009; accepted: 10 December 2009.
.0b013e3283367836
SN 0269-9370 Q 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins 1
Co
CE: Namrta; QAD/202105; Total nos of Pages: 13;
QAD 202105
2 AIDS 2010, Vol 24 No 00Introduction
Early immune events during HIV infection are associated
with the rate of subsequent disease progression [1]. Peak
viremia is accompanied by immune activation and CD4þ
T-cell depletion, particularly from the gastrointestinal
tract [2–4]. Although viral load subsequently declines,
immune activation persists, viral replication continues
and CD4þ T cells are progressively lost [1,5]. Immune
activation during HIV infection involves activation and
proliferation of most immune cells, including T cells, B
cells, natural killer (NK) cells and macrophages [6–9]. It
also includes increased production of pro-inflammatory
cytokines [4,10,11]. In the blood of acutely infected
individuals, an intense pro-inflammatory cytokine
‘storm’ is followed by immunoregulatory cytokine
production [4]. Pro-inflammatory cytokines enhance
HIV replication and CD4þ T-cell loss by directly
promoting proviral transcription, by recruiting and
activating CD4þ T-cell targets for HIV infection, and
by activation-induced apoptosis of bystander T cells [12–
14].
Although T-cell activation during early HIV infection is
known to influence subsequent disease progression [1],
the relationship between plasma cytokine production
during acute infection and disease prognosis has not been
investigated. Biomarkers that can be used to predict the
rate of HIV disease progression could be useful in the
clinical management of infected individuals and for the
evaluation of candidate HIV vaccines or microbicides
aimed at reducing the rate of disease progression, rather
than preventing infection [15,16]. Blood CD4 cell counts
and viral load measurements during primary, chronic and
advanced HIV infection are strongly predictive of
subsequent disease progression [16–19]. However, it
has been argued that coupling CD4 cell counts and viral
load measurements with estimates of T-cell proliferation
and activation during acute and/or chronic HIV infection
could provide significantly increased predictive power
[1,5,20,21]. Soluble markers of immune activation, such
as tumour necrosis factor-a receptor II p75 (TNF-RII),
neopterin and b2-microglobulin, are more easily
measurable in plasma samples than cellular activation
and have been found to predict HIV disease progression
with comparable efficiency to that with CD4 cell counts
and viral load measurements [17,22,23]. Although the
benefits of being able to predict, and possibly modify,
disease course during early HIV infection would be
substantial, the predictive value of immune activation
biomarkers has largely been investigated during chronic
HIV infection.
Here we have investigated the association between plasma
cytokine concentrations during acute infection and
established markers of long-term HIV disease progression
such as CD4 cell counts and viral load measurements. We
describe two models based on the easily measurablepyright © Lippincott Williams & Wilkins. Unauthoconcentrations of a small number of plasma cytokines that
can be used during acute infection to predict HIV
disease progression.Patients and methods
Study participants
Consenting women, recently infected with HIV-1
subtype C were recruited from HIV-negative cohorts
which were screened either monthly or 3 monthly for
HIV-1 infection as part of the CAPRISA 002 Acute
Infection Study [24]. Time of infection was defined as the
midpoint between the last HIVantibody negative test and
the first HIVantibody positive test or as 14 days prior to a
positive RNA PCR assay on the same day as a negative
HIV enzyme immunoassay. Plasma samples from 40
women at a median of 6 weeks postinfection (range 1–12)
and from 14 of these 40 women 25.5 weeks preinfection
(range 2–66) were available for analysis and were included
in this study. This study was approved by the University of
KwaZulu Natal and the University of Cape Town
Ethics Committees.
Markers of HIV-1 disease progression
Absolute blood CD4þ T-cell counts (cells/ml) were
measured using a FACSCalibur (BD, Franklin Lakes,
New Jersey, USA) flow cytometer at regular intervals
during HIV-1 infection (weekly for a month following
HIV-1 infection, fortnightly for 2 months, monthly for 9
months and quarterly thereafter). Plasma HIV-1 RNA
concentrations (copies/ml) were quantified using the
COBAS Amplicor HIV-1 Monitor version 1.5 or
COBAS Ampliprep/COBAS TaqMan 48 Analyser
(Roche Diagnostics, Branchburg, New Jersey, USA).
Viral load and CD4 cell count set points were defined as
the average CD4þ T-cell or viral load measurements of
three consecutive visits between medians of 47 and 55
weeks postinfection (range 37–69 weeks) overlying the
12-month postinfection time point.
Measurement of plasma cytokines
Thirty cytokines were measured in plasma from HIV-
uninfected and HIV-infected women using high-sensi-
tivity and human cytokine LINCOplex kits (LINCO
Research, St. Charles, Missouri, USA): interleukin (IL)-
1a, IL-1b, IL-1 receptor agonist (ra), IL-2, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-10, IL-12p40, IL-12p70, IL-13, IL-
15, IL-17, epidermal growth factor (EGF), eotaxin,
fractalkine, granulocyte colony-stimulating factor (G-
CSF), granulocyte–macrophage (GM)-CSF, interferon
(IFN)-g, IFN-g-induced protein (IP)-10, monocyte
chemotactic protein (MCP)-1, macrophage inflamma-
tory protein (MIP)-1a, MIP-1b, RANTES, soluble
CD40 ligand (sCD40L), transforming growth factor
(TGF)-a, TNF-a and vascular endothelial growth factor
(VEGF) [25]. The sensitivity of these kits ranged betweenrized reproduction of this article is prohibited.
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samples were assayed concurrently, on the same plates, in
order to avoid intra-assay variability. Each sample was
assayed twice using separate high-sensitivity kits, and the
average cytokine concentrations of the two assays were
used for all analyses. Data were collected using a Bio-Plex
Suspension Array Reader (Bio-Rad Laboratories Inc.,
Hercules, California, USA). Cytokine concentrations
below the lower limits of detection were reported as the
midpoint between the lowest concentration for each
cytokine measured and zero [11].
Statistical analyses
Univariate analyses were performed using GraphPad
Prism 5 (GraphPad Software, San Diego, California,
USA). Mann–Whitney U-test and Wilcoxon signed rank
test were used for unmatched and matched comparisons,
respectively. Spearman rank tests were used to test for
correlations. P values less than 0.05 were considered
significant. P values were adjusted using a false discovery
rate (FDR) step-down procedure [26] in order to reduce
false-positive results when multiple comparisons were
made.
Multivariate analyses were performed using Stata (Stata
Corp., College Station, Texas, USA). A multivariate
regression model was used to determine the cytokines
that best predicted 12-month viral load set points. Log-
transformed viral loads and cytokine concentrations were
used, except for IL-12p40, which was not normalized
following log transformation and was therefore included
as a categorical variable [response (1) versus no response
(0)]. Using univariate regression as a starting point,
cytokines that were significantly associated with viral load
set point, while controlling for each of the cytokines
already included, were added to the model in a stepwise
manner. Likelihood ratio tests were used to compare
nested models. Due to the relatively small size of the study
group, the sample of individuals used to develop the
model included all women who were followed for at least
12 months postinfection with complete cytokine datasets
(n¼ 31). Model performance evaluation was conducted
by repeatedly and randomly sampling subsets (n¼ 10)
consisting of three-quarters of the developmental sample
and reapplying the model. The validity of the assumptions
underlying the model was evaluated and outliers and
influential data points were determined using an analysis
of residuals. Predicted viral load set points were calculated
for each study participant using the standardized b-
coefficients of each of the cytokines included in the
model and the observed concentrations or response of
each cytokine in the following regression equation:
log 10li ¼ b0 þ b1X1i þ b2X2i þ    þ brXri
where li is the predicted viral load set point of the ith
patient whose log-transformed cytokine concentrations
or response were X1i, X2i,. . ., Xri.opyright © Lippincott Williams & Wilkins. UnauthA Cox proportional hazards model was used to
determine the cytokines significantly associated with
the time taken for study participant CD4 cell counts to
fall below 350 cells/ml for two or more consecutive
visits (survival time). Log-transformed cytokine con-
centrations were used, except in the case of IL-12p40.
Following univariate analysis, cytokines that were
significantly associated with survival time, while
controlling for each of the cytokines already included,
were added to the model in a stepwise manner. The
likelihood ratio test was used to compare nested models
and nonnested models were compared using Aikaike’s
information criterion (AIC), with the lowest AIC
indicating the best model in terms of fit. The sample for
model development included all women for whom
complete cytokine datasets were obtained (n¼ 35).
Model performance evaluation was conducted by
repeatedly sampling three-quarter subsets (n¼ 10) of
the developmental sample and reapplying the model.
The validity of the assumptions underlying the model
was evaluated and outliers and influential data points
were determined by an analysis of residuals.
Risk scores were calculated for each participant using the
b-coefficients of the Cox proportional hazards model [27]
and observed concentrations or response of cytokines
included in the model according to the following
equation:
li ¼ b1X1i þ b2X2i þ    þ brXri
where li is the risk score of the ith patient whose log-
transformed cytokine concentrations or response are X1i,
X2i,. . ., Xri. The study group was divided into three
groups based on the risk scores: low risk (0–15), medium
risk (15–20) and high risk (20–25).Results
Description of study participants
Forty black women from Durban, South Africa, recently
infected with HIV-1 were recruited into this study
(Table 1). Most of the women were unmarried (97.5%),
20% reported having more than one partner and 35%
were using injectable hormonal contraception at the time
of HIV infection. Sexually transmitted infections (STIs)
were common in this cohort, with 94.5% of women
having been diagnosed with at least one active infection
or bacterial vaginosis. The median acute infection CD4
cell count and viral load in this group of women were
477 cells/ml and 76 200 copies/ml, respectively (Table 2).
The median CD4 cell count and viral load set points of
women who were followed for at least 12 months
postinfection were 415 cells/ml and 39 783 copies/ml,
respectively.orized reproduction of this article is prohibited.
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Table 1. Demographic characteristics and prevalence of sexually transmitted infections in HIV-infected study participants.
Characteristics Value
Number of participants 40
Age in years [median (IQR)] 25 (21–37)
Marital status [N/total (% of women married)] 1/40 (2.5)
Number with >1 partner [N/total (% of women with >1 partner)] 8/40 (20)
Contraception use [N/total (% of women using contraception)] 14/40 (35)
Prevalence of STIs [N/total (% of women with lab diagnosed STI)] 37/39 (94.5)
Prevalence of multiple STIs [N/total (% of women with laboratory-diagnosed multiple STIs)] 31/36 (86.1)
Trichomonas vaginalis [N/total (% of women PCR positive for T. vaginalis)] 4/36 (11.1)
Chlamydia trachomatis [N/total (% of women PCR positive for C. trachomatis)] 6/36 (16.7)
Neisseria gonorrhoea [N/total (% of women PCR positive for N. gonorrhoea)] 6/36 (16.7)
Treponema pallidum [N/total (% of women with detectable T. pallidum antibody)] 2/40 (5.0)
Shedding HSV-2 [N/total (% of women PCR positive for HSV-2)] 1/36 (2.8)
HSV-2 IgG [N/total (% of women with detectable HSV-2 antibody)] 37/40 (92.5)
Bacterial vaginosis [N/total (% of women gram stain positive for BV)] 27/36 (75.0)
BV, bacterial vaginosis; HSV-2, herpes simplex virus type 2; IQR, interquartile range; STI, sexually transmitted infection.Plasma inflammatory cytokine concentrations
are elevated during acute HIV-1 infection and
are associated with peak viremia
Cytokine concentrations in plasma from HIV-uninfected
women (median of 25.5 weeks preinfection; n¼ 14)
were compared with samples from the same women
recently infected with HIV-1 (median of 6 weeks
postinfection; Fig. 1). Plasma concentrations of several
pro-inflammatory cytokines (IL-1a, IL-1b, IL-6, TNF-
a, IL-8, fractalkine, IP-10), anti-inflammatory IL-10 and
T-cell homeostatic cytokines (IL-2, IL-7) were increased
during acute HIV-1 infection compared with matched
preinfection samples. After adjusting for multiple
comparisons, IL-1a, IL-1b, TNF-a, IP-10 and IL-10
remained significantly elevated (Fig. 1a). Most cytokines
(24/30) tended to be elevated during acute infection
(Fig. 1b). Acute infection plasma concentrations of each
of the 30 cytokines were not associated with any of the
demographic characteristics listed in Table 1 (data not
shown). No associations between cytokine levels and
STIs were found by logistic regression analysis; however,
due to the small number of women without an STI
(n¼ 2) and the prevalence of multiple infections in this
group of participants, a more detailed analysis in a larger
cohort of women would be required to confirm
these findings.
It was found that IP-10, TNF-a, IL-1a, IL-1b, IFN-g,
and IL-10 correlated with the magnitude of viral loadpyright © Lippincott Williams & Wilkins. Unautho
Table 2. Clinical characteristics of study participants.
Clinical characteristics
CD4þ T-cell counts
Acute infection CD4þ T-cell count (cells/ml)
CD4þ T-cell count set point (cells/ml; average of three visits overlying 1
Plasma viral load
Acute infection plasma viral load (copies/ml)
Plasma viral load set point (copies/ml; average of three visits overlying
Blood CD4þ T-cell counts and plasma viral loads were determined for each
viral load set points were defined as the average CD4þ T-cell or viral loa
postinfection time point for each of the 36 women who were followed fo(Fig. 2; a heat map of the association between all 30
cytokines and viral load is shown in Supplementary
Fig. 1). After adjustment for multiple comparisons, IP-10
(adjusted P¼ 0.012) and TNF-a (adjusted P¼ 0.0165)
concentrations remained significantly associated with
viral load.
Plasma cytokine concentrations during acute
HIV-1 infection predict viral load set point
Univariate regression analysis was used to determine the
relationship between plasma cytokine concentrations
during acute HIV-1 infection and viral load set point
(Supplementary Table 1). As IL-12p70 was most strongly
associated with set point in the univariate analysis, this
cytokine was used as a starting point to develop a
multivariate model that included the cytokines that
together most strongly predicted viral load set point. Five
cytokines were incorporated into this model, each of
which was significantly associated with viral load set point
while controlling for the other cytokines included
(P< 0.005; Fig. 3a). A positive IL-12p40 response and
higher concentrations of IL-12p70 and IFN-g were
associated with lower viral load set point, whereas higher
concentrations of IL-7 and IL-15 were associated with
higher set point. The model was a good fit (F statistic
P< 0.0001) and, together, the concentrations of these
five cytokines in plasma during acute infection predicted
66% (adjusted R2¼ 0.6577) of the variation in viral set
point at 12 months postinfection.rized reproduction of this article is prohibited.
Median (IQR) N
477 (385–676) 40
2 months postinfection) 415 (314–607) 36
76 200 (117 775–339 250) 40
12 months postinfection) 39 783 (6613–104 825) 36
woman (n¼40) during acute HIV-1 infection. CD4þ T-cell count and
d measurements of three consecutive visits overlying the 12 months
r at least 12 months postinfection. IQR, interquartile range.
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Median cytokine concentration (IQR; pg/ml) 
Median cytokine 
Concentration change  
(IQR; pg/ml) 
P-value  
HIV negative HIV positive  
Inflammatory IL-1α 65.31 (0.32-211.9) 225.80 (130.1-668.3)  119.60 (55.12-515.5) 0.0002** 
IL-1β 0.27 (0.03-0.96) 1.42 (0.79-2.08)      0.98 (0.3-1.58) 0.0012** 
IL-6 2.44 (1.42-6.15)    4.52 (2.33-10.93)      1.30 (0.06-6.75) 0.0166* 
IL-12p40   8.23 (1.97-90.99)     1.97 (1.97-96.87)    0.00 (−6.26 to −13.63)  0.6406 
IL-12p70         0.05 (0.01-0.63)   0.03 (0.01-0.46) 0.00 (−0.17 to −0.18) 0.8311 
TNF-α 2.42 (1.66-3.41)   6.60 (4.86-8.30)      3.77 (2.58-5.77) 0.0001** 
Chemokines Eotaxin     42.77 (28.99-75.68)   58.85 (37.61-84.5)    10.58 (−3.6 to −20.59) 0.1909 
Fractalkine    34.63 (18.21-61.44)      60.52 (51.06-91.56)  32.26 (−6.69 to −62.63) 0.0295* 
IL-8  1.87 (1.07-3.73)     2.61 (1.36-5.21)      0.83 (0.11-1.62) 0.0295* 
IP-10     132.40 (81.38-223.5)  555.40 (188.2-1412)  220.30 (46.73-718) 0.0046** 
MCP-1       54.50 (24.6-130)      57.34 (31.72-144.7)      1.52 (−48.28 to −52.73) 0.7148 
MIP-1α 22.83 (10.26-47.7)      30.64 (23.54-41.01)  15.89 (−3.94 to −28.59) 0.0574 
MIP-1β   21.36 (13.02-42.87)      28.07 (18.63-40.66)    9.46 (−0.41 to −15.69) 0.1763 
RANTES      484.60 (436.8-1104)   467.10 (428.3-519.9)      0.00 (−222.7 to −28.74) 0.6221 
Anti-inflammatory IL-1ra   85.47 (45.84-335.5)   134.80 (72.96-309.4)    23.62 (−49.23 to −120.2) 0.391 
IL-10         3.21 (1.66-9.17)      18.16 (10.78-35.46)    12.17 (6.34-24.2) 0.0001** 
Growth factors TGF-α    4.47 (1.83-11.92)    3.99 (2.74-9.58)      0.09 (−1.81 to −4.97) 0.5879 
EGF     18.78 (10.97-54.13)    14.29 (11.4-51.85)    −6.80 (−14.36 to −17.54) 0.5016 
VEGF       18.88 (9.38-33.7) 14.49 (6.97-45.3) −2.79 (−14.04 to −9.06) 0.6257 
Hematopoietic IL-7  0.11 (0.05-1.04)    1.07 (0.59-2.68)   0.95 (−0.003 to −1.78) 0.0398* 
G-CSF    48.42 (25.94-108.4)      77.04 (42.64-123.4)     8.77 (−10.34 to −72.04) 0.1531 
GM-CSF   0.05 (0.01-0.35)    0.38 (0.01-1.03)      0.22 (−0.03 to −0.95) 0.083 
Adaptive sCD40L   5050.00 (2067-12601) 6713.00 (4225-10386) −199.9 (−2012 to −4694) 0.5879 
IFN-γ 0.63 (0.01-4.87)    3.76 (2.26-9.23)  2.87 (−0.55 to −6.63) 0.1272 
IL-2 2.21 (0.46-9.86)    10.87 (5.87-16.66)   7.74 (1.44-14.64) 0.0203* 
IL-4 33.68 (4.36-67.15)     30.42 (0.86-137.60)     2.11 (−9.42 to −83.79) 0.3575 
IL-5 0.17 (0.05-0.38)   0.28 (0.10-0.53) 0.09 (−0.01 to −0.2) 0.2166 
IL-13   8.31 (0.87-23.11)     6.65 (0.13-35.86)       0.13 (−2 to −7.42) 0.4697 
IL-15          0.04 (0.04-2.5)   2.01 (0.04-3.32)       0.29 (0-2.32) 0.1289 
IL-17 3.81 (0.34-5.64)         4.30 (2.49-5.9)   1.40 (−1.14 to −3.47) 0.5186 
Fig. 1. Comparison of plasma cytokine concentrations in women (n U 14) before infection (median 25.5 weeks preinfection) and
during acute HIV-1 infection (median 6 weeks postinfection). (a) Absolute IL-1a, IL-1b, IL-6, TNF-a, IL-8, fractalkine, IP-10, IL-10,
IL-7 and IL-2 concentrations were elevated in women with acute HIV-1 infection relative to concentrations before infection.
Wilcoxon signed ranks test was used for matched comparisons. P values less than 0.05 were considered significant and highlighted.
, Did not remain significant following false discovery rate adjustment for multiple comparisons. , Remained significant following
adjustment for multiple comparisons. (b) Fold upregulation in plasma cytokine concentrations following infection.
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Fig. 1. (Continued ).The validity of the assumptions underlying the model was
evaluated and outliers and influential data points were
determined using an analysis of residuals. Exclusion of
potential outliers from the dataset and reapplication of the
model did not substantially influence the strength of the
model. As the time from infection of sampling varied
widely (1–12 weeks postinfection), this was included
as a variable in the model. However, incorporation of
time from infection did not significantly influence the
strength of the model (adjusted R2¼ 0.6435), nor was
it significantly associated with viral load set point
(P¼ 0.996). Thus, the model presented does not include
this variable (Fig. 3a). It was furthermore found that the
concentrations of the cytokines included in the model did
not demonstrate any association with timing in relation to
the estimated date of infection. Upon evaluation of model
performance by reapplication of the model to 10
randomly chosen three-quarter subsets of the study
group, the influence of each variable on viral load set
point remained statistically significant and the direction-
ality of the relationships between the variables and set
point remained constant, indicating that the model
estimates are stable.
Predicted viral load set points were calculated for each
study participant using the standardized b-coefficients of
each of the cytokines included in the model (Fig. 3a) andpyright © Lippincott Williams & Wilkins. Unautho
Fig. 1. (Continued) P values less than 0.005 remained significant fo
bars (P<0.05) indicate cytokines that were significantly upreg
interquartile range.the observed concentrations or response of each cytokine
according to the following equation:
log10 ðVL set pointÞ ¼ 10:07þ ð0:61
 log10 IL-12p70Þ þ ð0:63
 log10 IL-7Þ þ ð0:49
 log10 IFN-gÞ þ ð0:45
 log10 IL-15Þ þ ð0:36
 IL-12p40 responseÞ
As expected, predicted viral load set points correlated well
with observed set points (Fig. 3b). The model including
IL-12p40, IL-12p70, IFN-g, IL-7 and IL-15 concen-
trations during acute infection fitted the viral set point
data of this cohort better (R2¼ 0.6577; P< 0.0001) than
either acute infection viral load (R2¼ 0.0941; P¼ 0.03)
or CD4 cell counts (R2¼ 0.0734; P¼ 0.0577) or the
combination of both (R2¼ 0.0800; P¼ 0.0917). The
substantially better R2 value of the cytokine model is due
in part to this model having been formulated with this
cohort. Although the significance of the relationship
between these cytokines and viral load set point was
strongly upheld upon reapplication of the model to three-
quarter subsets of the study group, assessment of the truerized reproduction of this article is prohibited.
llowing adjustment for multiple comparisons (red bars). Blue
ulated before adjustment for multiple comparisons. IQR,
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Fig. 2. Plasma inflammatory cytokine concentrations are associated with concurrent plasma viral loads in women with acute
HIV-1 infection. Only cytokines that correlated significantly with viral load before adjustment for multiple comparisons
are represented (P values and Spearman’s rho values below heat map). Women are ranked according to acute infection viral
load. Relative acute infection plasma cytokine concentrations of study participants are shown as a heat map, with each
row representing the cytokine concentrations in an individual woman and falling alongside her viral load. For each particular
cytokine, the concentrations found in this group of women were ranked and assigned an appropriate colour ranging from white
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8 AIDS 2010, Vol 24 No 00predictive power of this model would require application
of the model to an entirely different, larger dataset.
Plasma cytokine concentrations during acute
HIV-1 infection predict time taken for CD4 cell
counts to fall below 350 cells/ml
We next determined a subset of cytokines that were most
significantly associated with the time taken for participant
CD4 cell counts to fall below 350 cells/ml using a Cox
proportional hazards model. Using univariate survival
analysis as a starting point (Supplementary Table 2),
cytokines that were significantly associated with survival
time were added to the model in a stepwise manner.
Plasma concentrations of IL-1a, eotaxin and IL-7 were
significantly associated with increased risk of CD4 loss,
whereas GM-CSF and IL-12p40 were associated with
reduced risk (P< 0.05; Fig. 4a). The model was a good fit
(x2 test; P< 0.0001) and exclusion of potential outliers
from the dataset and reapplication of the model did not
substantially influence the strength of the model. Time
(postinfection) of sampling was included in the model;
however, this variable was not significantly associated
with survival time (P¼ 0.357), whereas the relationships
between each of the cytokines and survival time remained
significant. Reapplication of the model to 10 randomly
chosen three-quarter subsets of the study group revealed
that model performance was good, with the directionality
of the relationships between each of the variables and
survival time remaining constant.
Risk scores were calculated for each participant using the
b-coefficients of the Cox proportional hazards model
(Fig. 4a) and observed acute infection plasma concen-
trations or response of each of the cytokines included in
the model according to the following equation:
risk score ¼ 1:31ðlog10 eotaxinÞ þ 2:25ðlog10 IL-1aÞ
þ 0:72ðlog10 IL-7Þ  2:58
ðIL-12p40 responseÞ  0:81
ðlog10 GM-CSFÞ
HIV-1-infected participants were divided into low-risk,
medium-risk or high-risk groups according to their risk
scores. Women in the high-risk group (n¼ 11) experi-
enced rapid CD4þ T-cell loss to below 350 cells/ml
during the study period (median time to event: 15 weeks
postinfection; Fig. 4b), with the exception of a single
woman who left the study at 52 weeks postinfection.
Women in the low-risk group (n¼ 7) maintained CD4
cell counts above 350 cells/ml during the study (median
follow-up: 76 weeks postinfection). The Cox pro-
portional hazards model including acute infection IL-pyright © Lippincott Williams & Wilkins. Unautho
Fig. 2. (Continued) (lowest concentration) to red (highest concentra
colour. IP-10, TNF-a, IL-1a, IL-1b, IFN-g and IL-10 correlated with
remained significantly correlated with viral load following adjustm1a, eotaxin, IL-7, GM-CSF and IL-12p40 was a better
model in terms of fit (AIC 85.09) when compared with
models including only acute infection CD4 cell count
(AIC 113.25) or viral load (AIC 124.81) or the
combination of both (AIC 112.05).Discussion
Immune activation during HIV infection has been
identified as a major contributor to HIV disease
progression and is the product of inflammatory responses
to HIV-encoded Toll-like receptor ligands, microbial
translocation and the homeostatic response to CD4þ
T-cell depletion [1,8,9,28,29]. Here, we propose two
models, based on a restricted set of plasma cytokines
measured during acute HIV-1 infection, which are useful
for the prediction of viral load set point and CD4 decline.
We show that concentrations of IL-7, IL-12p40, IL-
12p70, IFN-g and IL-15 during acute infection better
predicted viral load set point than acute infection viral
load, acute infection CD4 cell counts or the combination
of both. Further, we show that plasma concentrations of
IL-7, IL-12p40, IL-1a, eotaxin and GM-CSF during
acute infection were strongly predictive of CD4 loss.
HIV viral loads in plasma and systemic CD4 cell counts
are widely accepted predictors of HIV disease progression
[16–19]. In addition, T-cell proliferative capacity and
activation states during early and chronic HIV infection
are predictive of disease progression [1,5,20,21]. Con-
centrations of soluble biomarkers such as TNF-RII,
neopterin and b2-microglobulin during chronic infection
have also been shown to predict progression to AIDS
and/or CD4 decline with a degree of accuracy
comparable to that of CD4 cell counts and viral load
measurements [17,22,23]. Although biomarkers of HIV
disease progression identified during chronic infection are
useful for determining rates of progression to AIDS, the
ability of these markers to predict clinical course at earlier
infection stages has not been tested.
We and others have shown that early HIV-1 infection is
accompanied by a robust plasma pro-inflammatory
cytokine response [4,11]. Here, we demonstrate that
plasma immunoregulatory IL-10 and pro-inflammatory
IL-1a, IL-1b, TNF-a and IP-10 were elevated in
women with acute HIV-1 infection relative to preinfec-
tion. Upregulated pro-inflammatory cytokines, IP-10
and TNF-a, were significantly associated with higher
HIV viral load, suggesting that the observed inflamma-
tory cytokine ‘storm’during acute infection is induced, atrized reproduction of this article is prohibited.
tion). Repeated values were assigned the same rank and hence
viral load. PID, patient identity number. #, IP-10 and TNF-a
ent for multiple comparisons. , Not done.
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Number of observations = 31 
Adjusted R  = 0.6577 2




β-coefficient 95% CI PSE Standard
β-coefficient 
Per positive response 
−0.36 0.47 2.07  0.003 0.39 −1.27 IL-12p40 
Per 1 log10 pg/ml increase 
−0.61 0.31 0.72 < 0.001     0.10 −0.51 IL-12p70 
IFN-γ −0.49 0.19 0.57 < 0.001 0.09 −0.38 
 0.63 1.06 0.42 < 0.001 0.15  0.73 IL-7 
 0.45 0.48 0.16 < 0.001 0.08  0.32 IL-15 
Fig. 3. Acute infection IL-12p40, IL-12p70, IFN-g, IL-7 and IL-15 concentrations are predictive of viral load set point. (a) Each
cytokine was significantly associated with viral load set point (P values <0.005). The model fitted the data significantly
(P> F<0.0001), and together the five cytokines predicted 65.77% (adjusted R2¼0.6577) of the variation in set point. (b) Set
point viral loads as predicted by the model correlate with observed set point viral loads.least in part, in response to the presence of HIV
replication and products.
We found that higher concentrations of IL-12p70, IL-
12p40 and IFN-g were associated with lower viral set
point, whereas IL-12p40 and GM-CSF were associated
with prolonged maintenance of CD4 cell counts above
350 cells/ml. Production of these cytokines is partly
regulated by a positive feedback loop, with IFN-g and
GM-CSF promoting IL-12p70 production and IL-12p70
in turn stimulating IFN-g and GM-CSF secretion [30–
33]. IL-12p70 and IFN-g promote Th1 differentiation,
favouring cell-mediated immunity and inhibiting Th2
responses [34–36]. IFN-g has previously been identified as
a correlate of better disease prognosis in HIV infection and
was positively associated with CD8þ T-cell and activated
NK cell counts [37,38]. In simian immunodeficiency virus
(SIV)-infected macaques, IL-12p70 treatment during
acute infection was associated with decreased viral loads,
increased CD8þ NK and T cells, reduced naive CD4þ Topyright © Lippincott Williams & Wilkins. Unauthcells expressing homing markers, retention of HIV-specific
cytotoxic T lymphocyte (CTL) and prolonged survival
[39]. IFN-g, GM-CSF and IL-12p40 are also principal
macrophage-inducing cytokines, promoting their pro-
duction, recruitment and/or activation [40–43].
In this study, elevated IL-7 and IL-15 concentrations were
associated with higher viral load set point, whereas IL-7,
IL-1a and eotaxin were associated with greater CD4 loss.
Eotaxin and IL-1a are chemotactic for T cells, potentially
recruiting targets for HIV infection [44,45]. IL-1a has
additionally been found to strongly induce NF-kB
activation, which binds to HIV-long terminal repeat
sequences and in so doing may directly upregulate HIV
replication [12,46]. IL-7 and IL-15 are the principal
regulators of CD4þ and CD8þ T-cell homeostasis
[47,48]. Picker et al. have proposed a model in which
the balance between CD4þ central memory (TCM) and
effector memory T cells (TEM) dictates the rate of HIV
disease progression [49]. TEM home to effector sites andorized reproduction of this article is prohibited.
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LR χ2  = 32.79 




Hazard ratio SE P 95% CI β-coefficient 
Per positive response 
IL-12p40 0.08 0.07 0.005 0.01 0.46        −2.58 
Per 1 log10 pg/ml increase  
GM-CSF 0.44 0.11 0.001 0.27 0.73        −0.81 
IL-1α 9.49 6.03   < 0.001 2.73 32.97 2.25 
Eotaxin 3.71 2.00 0.015 1.29 10.67 1.31 
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Fig. 4. Acute infection IL-12p40, GM-CSF, IL-1a, eotaxin and IL-7 concentrations were associated with the time taken for the
study participant CD4 cell counts to fall below 350 cells/ml. (a) Each cytokine was significantly associated with survival time (P
values <0.05) and the model fitted the data well (P>x2<0.0001). (b) Kaplan–Meier survival estimates of women grouped
according to risk score. Risk scores were calculated for each participant using the b-coefficients of each cytokine included in the
Cox proportional-hazards model, and women were divided into low (0–15), medium (15–20) and high (20–25) risk groups based
on risk scores. Women in the high-risk group experienced rapid CD4 cell count loss, whereas women in the low-risk group
maintained CD4 cell counts above 350 cells/ml for the duration of follow-up. Each dash indicates a time point at which an
individual woman left the study (censored event).serve as the primary targets for HIV infection and
destruction, but it appears to be their longer-lived TCM
precursors, which replenish these populations and decay
more gradually, that determine the tempo of disease
progression. Higher IL-7 levels are associated with
lymphopenic states during HIV infection [9,50]. IL-7
selectively induces proliferation of naive T cells and TCM
cells and it has been proposed that, at high levels, IL-7
may disrupt the normal naive/memory differentiation
pathway by inducing memory-like characteristics on
naive cells. Exhaustion or excessive differentiation could
reduce the longevity of this population, its ability to self-
renew, expand and differentiate upon antigen stimulationpyright © Lippincott Williams & Wilkins. Unautho[48]. IL-15 can induce antigen-independent proliferation
and differentiation of TEM from TCM [48,51]. Thus,
elevated IL-15 levels during early infection may accelerate
the loss of TEM, thereby depleting TCM more rapidly.
Additionally, increased IL-15 levels during acute SIV
infection led to an upregulation of CD4 expression on
memory CD4þ T cells which increased in their
susceptibility to SIV infection [52]. We recently
demonstrated that a greater destruction of the CD8þ
TCM compartment and accumulation of CD8
þ TEM
correlated with a higher viral set point [53]. This may lead
to exhaustion of CD8þ resources required for the control
of HIV and other infections.rized reproduction of this article is prohibited.
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activation in HIV infection [54]. Polyclonal B-cell
activation and differentiation, together with the destruc-
tion of germinal centres, has recently been described in
acute HIV infection [55], likely resulting in the
characteristically ‘delayed’ antibody response to HIV.
Early dysregulation of the B-cell response due to elevated
IL-15 levels may lead to reduced viral control, as reflected
in higher set point viral loads. Thus, memory CD4þ T-
cell dysfunction and depletion, CD8þ T-cell exhaustion
and B-cell dysfunction may partly be driven by elevated
levels of IL-7 and IL-15 from the earliest stages of
infection, setting the course for accelerated disease
progression.
We found that anti-inflammatory IL-10 was significantly
elevated during acute HIV-1 infection, was correlated
directly with acute infection viral loads before adjustment
for multiple comparisons and was associated with greater
risk of CD4þ T-cell loss in a univariate Cox survival
analysis. Although IL-10 reduces HIV replication in
macrophages [56], this cytokine may contribute to HIV
persistence by suppressing effector T-cell responses [57–
59]. In support, it has been demonstrated that serum IL-
10 levels increase with disease progression in HIV-
infected individuals [60]. Additionally, regulatory T cells,
an important source of IL-10 [61], were shown to
correlate inversely with the magnitude of SIV-specific
CTL responses during acute SIV infection and may
contribute to viral persistence [62].
In conclusion, we demonstrate the potential to use plasma
cytokine concentrations during acute HIV-1 infection to
predict subsequent disease progression. Two clusters of
cytokines were more strongly predictive of viral load set
point and CD4þ T-cell loss than either acute infection
CD4 cell counts, viral loads or both combined. The
identification of cytokine biomarkers, which are indica-
tive of early immune activation, predictive of subsequent
HIV disease prognosis and can be measured directly in
plasma samples from individuals with acute/early HIV
infection, may inform approaches for evaluating the
ability of therapeutic HIV vaccines and microbicides to
control HIV infection.Acknowledgements
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